AREVIR-GenaFor-Meeting 2009

Program

Please visit the website, where our chairs give a summary of their sessions

Donnerstag, 23. April 2009

Zeit	Vorträge
09:00 - 09:15	Begrüßung durch den Direktor des Forschungszentrum caesar, Jürgen Reifarth
09:15 - 09:30	Sicht des Patienten Hans Thomas Sedlmayer
09:30 - 11:50	Chair: Dieter Glebe, Maria Fraune HBV Resistenzbestimmung, Genotypisierung, Internet tools up-date, Klinische Anwendung/Primärresistenz bei HBV, Phänotypische Resistenztestung - das Projekt HOPE, Escape-Varianten, WHO-Standards für verschiedene Genotypen, Daten verschiedener Arbeitsgruppen, Kommerzielle Assays
	HIV-GRADE HBV-Tool Martin Obermeier
	Geno2pheno[HBV] Rolf Kaiser
	Therapy with oral antivirals in HBV infections with resistance to nucleos(t)ide analogues Balazs Fülöp
	Hepatitis B -- Primäre Resistenz Andreas Erhardt
	BMBF consortium: Hepatitis B therapies optimized by phenotypic evaluation (HOPE) Oliver Schildgen, Hospital Mehrheim, Köln
	Optimizing Phenotypic HBV Drug Resistance Testing for High Throughput Ke Zhang
	Occult hepatitis B virus infections Dieter Glebe
	Hepatitis-B-virus mutations in the major hydrophilic loop Maria Fraune
	HBV Genotype Panel Michael Chudy
12:10 - 13:30	Chair: Lutz Gürtler, Melanie Balduin HIV-2 Epidemiologie, Tools zur Bestimmung der Viruslast, Resistenztestung, Therapieauswahl
	HIV-2: epidemiology, diagnosis and follow-up: the Portuguese experience Ricardo Camacho
	HIV-2 -- Experiences in Munich Josef Eberle
	HIV-2 Resistance -- Interpretation and Case Report Martin Stürmer
	HIV-2: From a clinical point of view Dr. Björn Jensen
13:30 - 14:30	Mittagessen
14:30 - 15:30	Chair: Stefan Esser, Nadine Sichtig HIV Integrase / Coronet
	HIV-1 Integrase: not just an other HIV enzyme Linos Vandekerckhove
	Integrase Inhibitoren Stefan Esser
	Coronet -- A European Integrase Resistance Study Group
	Evolution of raltegravir resistance during therapy Nadine Sichtig
	Geno2pheno[integrase] André Altmann
15:45 - 16:45	Chair: Mark Oette Verbund - Projekte Teil I RKI-Serokonverter, RegaDB, RESINA, CHAIN, EuResist, Daten anderer Arbeitsgruppen
	The German HIV-1 Seroconverter Cohort Barbara Bartmeyer
	RegaDB Pieter Libin
	ART in patients with primary HIV-resistance -- The RESINA study Stefan Reuter
16:45 - 17:00	Kaffeepause
17:00 - 17:45	Chair: Mark Oette The EVE study
	The "EVE" Study Maurizio Zazzi

Freitag, 24. April 2009

Zeit	Vorträge
09:00 - 10:15	Chair: Herbert Pfister, Jens Verheyen Bedeutungen der Mutationen in Gag / Protease
	HIV can modulate Gag NC/p1 cleavage and thereby affect PI susceptibility and viral replicative capacity Monique Nijhuis
	Prevalence of therapy-associated HIV gag CS mutations Jens Verheyen
	CTL Recognition of Gag Cleavage Sites Thomas Harrer
	HIV-1-specific CTL and Drug Resistance Sandra Müller, Uni Erlangen
	A new class of drugs: maturation inhibitors -- new hope or dead end Jens Verheyen
	Prediction of Bevirimat Resistance in HIV-1 Dominik Heider
10:30 - 13:30	Chair: Saleta Sierra Aragon, Christoph Wyen HIV: Coreceptor prediction update, Ultra deep sequencing
	Clinical Use of CCR5 Antagonists Björn Jensen
	Genotypic prediction of viral co-receptor tropism: Correlation with enhanced Trofile Anna Maria Geretti
	Coreceptor Tropism of HIV-1 -- Development of a viros-free Assay and HIV-1 Tropism Study -- Comparison of Trofile^TM and Geno2pheno[coreceptor] Eva Heger
	Update on geno2pheno[coreceptor]: recent integrations and results Alexander Thielen
	HIV tropism assessment using next generation sequencing Mattia CF Prosperi
	Tropism Testing with XTrack^C Heinz Stucki
	V3 Loop Sequence Space Analysis Kasia Bozek
	The Berlin Maraviroc cohort -- Influence of genotypic tropism testing results on therapeutic outcome Martin Obermeier
	Analysis of HIV evolution in a stem cell transplanted HIV patient: indications for in silico modelling Christel Kamp
	Tropism, seen through the "454-loupe" Martin Däumer
13:30 - 14:30	Mittagessen
14:30 - 16:30	Chair: Francesca Incardona, Daniel Hoffmann Verbund / Projekte Teil II CORUS, HIV Cell Entry / MedSys, Kompetenznetz HIV/AIDS, Assurance, HIV-Grade, Arevir
	CORUS Project -- Coreceptor usage as a marker for specific HIV diagnostics with high sensitivity Susanna Trapp
	Coreceptor Usage Prediction and Model Interpretation J. Nikolaj Dybowski
	Comparative analysis of HIV-1 attachment and fusion efficiency Manon Eckhardt
	The CompNet resistance module: Current status Klaus Jansen
	The Role of External Quality Assessment Schemes for Laboratory Proficiency and Standardization Hans-Peter Grunert
	HIV GRADE Update Hauke Walter
	Arevir -- Analysis of resistance mutations of HI-Virus Eugen Schülter
	Bias-aware learning for HIV therapy screening Jasmina Bogojeska
16:30 - 17:00	Kaffeepause
17:00 - 18:00	Chair: Thomas Lengauer, Martin Däumer HIV and Fitness
	Rega Institute for Medical Research Kristof Theys
	Viral fitness Hauke Walter
	Can we blame fitness for surprising therapy outcomes? André Altmann
18:00 -	Schlusswort Rolf Kaiser

Download Program (PDF)

Welcome to Genafor − Open Services for Medical Research

AREVIR-GenaFor-Meeting 2009

Program

Donnerstag, 23. April 2009

Freitag, 24. April 2009